PIACENTINI, Federico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.710
EU - Europa 15.100
AS - Asia 13.100
SA - Sud America 1.789
AF - Africa 356
OC - Oceania 75
Continente sconosciuto - Info sul continente non disponibili 23
Totale 55.153
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.160
IT - Italia 5.038
SG - Singapore 3.884
CN - Cina 3.184
GB - Regno Unito 2.540
IE - Irlanda 2.197
HK - Hong Kong 1.492
VN - Vietnam 1.395
BR - Brasile 1.295
DE - Germania 1.181
SE - Svezia 1.025
BD - Bangladesh 770
FR - Francia 567
FI - Finlandia 541
RU - Federazione Russa 484
UA - Ucraina 401
IN - India 398
KR - Corea 365
CA - Canada 307
ID - Indonesia 295
TR - Turchia 288
NL - Olanda 212
BG - Bulgaria 179
AR - Argentina 164
JP - Giappone 144
TW - Taiwan 144
MX - Messico 135
IQ - Iraq 120
ES - Italia 107
PL - Polonia 104
ZA - Sudafrica 81
LT - Lituania 79
PK - Pakistan 76
CO - Colombia 75
AU - Australia 72
CL - Cile 71
BE - Belgio 65
MY - Malesia 64
EC - Ecuador 61
AE - Emirati Arabi Uniti 60
EG - Egitto 59
VE - Venezuela 54
AT - Austria 53
CZ - Repubblica Ceca 45
SA - Arabia Saudita 43
IR - Iran 42
PH - Filippine 42
MA - Marocco 39
JO - Giordania 38
KE - Kenya 34
TH - Thailandia 31
CH - Svizzera 30
NP - Nepal 29
PY - Paraguay 29
RO - Romania 29
UZ - Uzbekistan 28
MD - Moldavia 25
AL - Albania 23
IL - Israele 22
TN - Tunisia 22
AZ - Azerbaigian 21
DZ - Algeria 20
GR - Grecia 20
DO - Repubblica Dominicana 19
HU - Ungheria 19
ET - Etiopia 17
EU - Europa 17
NG - Nigeria 17
PT - Portogallo 17
JM - Giamaica 16
PE - Perù 15
CR - Costa Rica 14
DK - Danimarca 14
LB - Libano 14
SI - Slovenia 14
SY - Repubblica araba siriana 14
BO - Bolivia 13
MK - Macedonia 13
HN - Honduras 12
RS - Serbia 12
LV - Lettonia 11
BH - Bahrain 10
KZ - Kazakistan 10
OM - Oman 10
UY - Uruguay 10
AO - Angola 9
BY - Bielorussia 9
CI - Costa d'Avorio 9
PA - Panama 9
CY - Cipro 8
MT - Malta 8
PR - Porto Rico 8
QA - Qatar 8
SK - Slovacchia (Repubblica Slovacca) 8
HR - Croazia 7
KG - Kirghizistan 7
SN - Senegal 7
TT - Trinidad e Tobago 7
BB - Barbados 6
KH - Cambogia 6
Totale 55.022
Salva come PNG Salva come JPEG
Città #
Ashburn 2.664
Singapore 2.593
Santa Clara 2.478
Dublin 2.189
Fairfield 1.752
Hong Kong 1.437
Chandler 1.433
Southend 1.325
San Jose 1.209
Woodbridge 1.013
Houston 795
Beijing 758
Council Bluffs 745
Dearborn 735
Seattle 726
Nyköping 668
Ann Arbor 666
Hefei 644
Wilmington 624
Jacksonville 609
Cambridge 536
London 522
Dallas 520
New York 507
Milan 472
Ho Chi Minh City 440
Los Angeles 430
Helsinki 402
The Dalles 365
Rome 341
Modena 338
Hanoi 312
Seoul 303
Chicago 246
Jakarta 229
Munich 209
Shanghai 201
Lauterbourg 197
Bologna 190
San Diego 183
Princeton 174
Sofia 169
Moscow 158
Eugene 141
Buffalo 139
Izmir 132
São Paulo 124
Frankfurt am Main 118
Columbus 116
Dong Ket 112
Orem 109
Fremont 106
Redwood City 104
Naples 101
Tokyo 90
Phoenix 80
Bremen 77
Salt Lake City 77
Florence 76
Boardman 74
Warsaw 74
Guangzhou 70
Falls Church 67
Brooklyn 66
Toronto 66
Turin 66
Reggio Emilia 64
Bari 60
Redondo Beach 57
Taichung 56
Atlanta 55
Chennai 55
Da Nang 55
Genoa 55
Parma 52
Tampa 52
Mumbai 50
Baghdad 49
Brussels 49
Haiphong 49
Montreal 49
Palermo 47
Amsterdam 46
Nuremberg 44
Turku 44
Denver 43
Norwalk 43
Elk Grove Village 40
Ottawa 40
Rio de Janeiro 40
Johannesburg 38
Mexico City 38
Des Moines 37
San Francisco 37
Nanjing 36
Paris 36
Santiago 36
Verona 36
San Giuliano Milanese 35
Stockholm 35
Totale 36.250
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.165
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 630
Oxford Manuale di Medicina Clinica 584
Abemaciclib: eventi avversi e riduzione di dose. 552
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 491
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 455
RISULTATI DELLA RADIOTERAPIA PANENCEFALICA (WBRT) NELLE METASTASI CEREBRALI DA CARCINOMA DELLA MAMMELLA: STUDIO RETROSPETTIVO SUL RUOLO PROGNOSTICO DEI FATTORI BIOLOGICI 447
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer 440
Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor 439
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 432
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 430
GD2 expression in breast cancer. 427
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 425
SVILUPPO DI IPOGAMMAGLOBULINEMIA IN PAZIENTI TRATTATI CON IMATINIB PER LEUCEMIA MIELOIDE CRONICA O TUMORI STROMALI GASTROINTESTINALI 420
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 414
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial 411
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 403
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 398
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 397
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 395
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 392
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 389
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 380
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 380
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 375
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 375
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 374
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 372
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 372
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER 368
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 366
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 363
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 363
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial 362
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 362
Molecular Profile, as detected with Mass-Array Spectrometry (Sequenom platform), in primary and metastatic breast carcinoma treated with Exemestane + Everolimus 358
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 357
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 355
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 355
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 354
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 353
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 347
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 345
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 344
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 339
Tumor Stroma Manipulation By MSC 334
Achievements and unmet needs in the management of advanced ovarian cancer 333
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 331
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 330
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 325
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer. 324
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 323
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 320
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 320
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 317
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 317
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 316
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 316
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 313
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 312
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 311
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 309
Immune characterization of breast cancer metastases: prognostic implications. 309
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 309
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 309
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 308
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 307
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 305
Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP guidelines: a single institution analysis. 305
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 303
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 299
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 299
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 296
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 296
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 291
Breast Location for De Novo Extramedullary Myeloid Sarcoma 290
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 290
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 288
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 287
Preoperative Carboplatin–Paclitaxel–Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study 286
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 283
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer 282
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 280
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING (NGS) MULTI-GENE PANEL 278
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in patients with HER2-positive operable breast cancer 278
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 276
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 274
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 272
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 271
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 271
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 270
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 269
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 266
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 265
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 265
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 265
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). 263
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 263
Prognostic Factors for Breast Cancer: an Immunomorphological Update 261
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 261
Totale 35.096
Salva come PNG Salva come JPEG
Categoria #
all - tutte 191.493
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 191.493
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.347 133 383 286 129 124 264 152 199 366 301 594 416
2022/20236.486 494 585 344 417 410 514 111 388 2.573 114 325 211
2023/20243.725 179 203 239 292 496 314 342 569 150 204 298 439
2024/20259.842 357 209 270 727 1.882 1.501 628 693 967 583 772 1.253
2025/202619.262 1.211 601 1.616 1.833 2.728 1.255 2.462 1.043 1.812 1.947 1.506 1.248
2026/2027596 596 0 0 0 0 0 0 0 0 0 0 0
Totale 55.546